Substance / Medication

Eplerenone

Overview

Active Ingredient
eplerenone
RxNorm CUI
298869
Labeler: AvKAREUpdated: 2026-01-14T00:00:00.000ZFull label on DailyMed

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Eplerenone and Spironolactone for Chronic Central Serous Chorioretinopathy: A Systematic Review and Meta-Analysis.
Huang Ryan S, Mihalache Andrew, Benour Ali et al. · Am J Ophthalmol · 2025
PMID: 40513762Meta-Analysis
Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis.
Elshahat Ahmed, Mansour Ahmed, Ellabban Mohamed et al. · BMC Cardiovasc Disord · 2024
PMID: 39271992Meta-AnalysisFull text (PMC)
Efficacy and safety of eplerenone treatment for patients with diabetic nephropathy: A meta-analysis.
Hu Honglei, Zhao Xiaodong, Jin Xingqian et al. · PLoS One · 2022
PMID: 35324976Meta-AnalysisFull text (PMC)
Eplerenone for hypertension.
Tam Tina Sc, Wu May Hy, Masson Sarah C et al. · Cochrane Database Syst Rev · 2017
PMID: 28245343Meta-AnalysisFull text (PMC)
Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
Pelliccia Francesco, Patti Giuseppe, Rosano Giuseppe et al. · Int J Cardiol · 2014
PMID: 25499383Meta-Analysis
Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial.
Kobayashi Masatake, Yamashina Akira, Satomi Kazuhiro et al. · Cardiovasc Diabetol · 2025
PMID: 40121450RCTFull text (PMC)
The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy: A Randomized Clinical Trial.
Papapostolou Stavroula, Iles Leah, O'Brien Jessica et al. · JACC Heart Fail · 2025
PMID: 40243979RCT
Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure.
Kobayashi Masatake, Yamashina Akira, Satomi Kazuhiro et al. · Int J Cardiol · 2024
PMID: 39181408RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Eplerenone (substance)
SNOMED CT
407010008
UMLS CUI
C0961485
RxNorm CUI
298869
Labeler
AvKARE

Clinical Data

This intervention maps to 2 entities in the Healos knowledge graph.

2
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.